Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human umbilical cord mesenchymal stem cells (Nanjing Drum-Tower Hospital)
- Development stage
- Unknown
- Lead developer
- Nanjing Drum-Tower Hospital
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Human umbilical cord mesenchymal stem cells (hUC-MSCs) are an allogeneic cell-based biologic therapy developed by Dr. Lingyun Sun and colleagues at the Affiliated Drum Tower Hospital of Nanjing University Medical School. These mesenchymal stem cells are isolated from human umbilical cord tissue and possess potent immunomodulatory properties. The therapy is primarily investigated for the treatment of refractory lupus nephritis (LN), particularly classes III, IV, and V. The mechanism of action involves the suppression of overactive immune responses by increasing T-regulatory (Treg) cell populations, reducing Th1 and Th17 cell subsets, and modulating B cell function and antibody production. Clinical studies, including Phase 2 randomized trials, have evaluated its efficacy and safety compared to standard immunosuppressants like mycophenolate mofetil (MMF), showing promising response rates in patients who are refractory to conventional therapy.
- Other names
- allogeneic human umbilical cord mesenchymal stem cellsumbilical cord-derived mesenchymal stem cells
Beyond the preview
Go deeper on human umbilical cord mesenchymal stem cells (Nanjing Drum-Tower Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human umbilical cord mesenchymal stem cells (Nanjing Drum-Tower Hospital).